

8-K
1
d8k.txt
FORM 8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2001

COMMISSION FILE NUMBER 1-12584

— DELAWARE — SHEFFIELD PHARMACEUTICALS, INC. — 13-3808303
(State of other jurisdiction of — (Exact name of registrant as — (I.R.S. Employer
incorporation or organization) — specified in its charter) — Identification No.)

14528 South Outer Forty Road, Suite 205, St. Louis, Missouri — 63017

— (Address of principal executive officers) — (Zip Code)

— Registrant's telephone number, including area code (314) 579-9899

— Not Applicable

— (Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

— On October 1, 2001, Sheffield Pharmaceuticals, Inc., a Delaware corporation, issued a press release, a copy of which is attached hereto as Exhibit 99 and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

Exhibit Number — Description

— 99 — Press Release dated October 1, 2001 issued by Sheffield
— Pharmaceuticals, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: October 11, 2001 By: /s/ Scott Hoffmann

Scott Hoffmann

Vice President and

Chief Financial Officer